Alrefai Mohammad T, Murali Divya, Paul Arghya, Ridwan Khalid M, Connell John M, Shum-Tim Dominique
Division of Cardiac Surgery, McGill University Health Center, Montreal, QC, Canada ; Division of Surgical Research, McGill University Health Center, Montreal, QC, Canada ; King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Department of Chemical and Petroleum Engineering, School of Engineering, University of Kansas, Lawrence, KS, USA.
Stem Cells Cloning. 2015 May 14;8:81-101. doi: 10.2147/SCCAA.S54204. eCollection 2015.
Stem cell therapy and tissue engineering represent a forefront of current research in the treatment of heart disease. With these technologies, advancements are being made into therapies for acute ischemic myocardial injury and chronic, otherwise nonreversible, myocardial failure. The current clinical management of cardiac ischemia deals with reestablishing perfusion to the heart but not dealing with the irreversible damage caused by the occlusion or stenosis of the supplying vessels. The applications of these new technologies are not yet fully established as part of the management of cardiac diseases but will become so in the near future. The discussion presented here reviews some of the pioneering works at this new frontier. Key results of allogeneic and autologous stem cell trials are presented, including the use of embryonic, bone marrow-derived, adipose-derived, and resident cardiac stem cells.
干细胞疗法和组织工程代表了当前心脏病治疗研究的前沿领域。借助这些技术，针对急性缺血性心肌损伤和慢性、否则不可逆的心肌衰竭的治疗正在取得进展。目前心脏缺血的临床管理主要致力于恢复心脏灌注，但并未解决供应血管阻塞或狭窄所造成的不可逆损伤。这些新技术的应用尚未完全确立为心脏病管理的一部分，但在不久的将来将会如此。本文的讨论回顾了这一全新前沿领域的一些开创性工作。介绍了同种异体和自体干细胞试验的关键结果，包括胚胎干细胞、骨髓来源干细胞、脂肪来源干细胞和心脏驻留干细胞的使用情况。
